glp-1 cardiovascular outcomes 2025 news The Big Trial of a drug (Wegovy) to Reduce Major Events Alarming rise in weight loss

Dysesthesia signal (Phase 3) TRIUMPH-4 topline results, released December 11, 2025, reported dysesthesia in about 20.9% of participants at the highest dose

7 Key Performance Indicators: Average Weight Loss: Participants lost an average of 4.9 kg by the trial endpoint

[1] The MHRA has issued guidance regarding the risk of pancreatitis with GLP-1 receptor agonists, and whilst rare, this serious adverse effect requires immediate medical attention

In comparison, the highest available doses of tirzepatide (Mounjaro

Start your intake What Ozempic actually is Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist